Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Generic Drugs Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Generic Drugs Market

5.1. Covid-19: generic drugs Industry Impact

5.2. generic drugs Business Impact Assessment: Covid-19

5.2.1. Services Challenges/Disruption

5.2.2. Market Trends and generic drugs Opportunities in the COVID-19 Landscape for Major Markets

5.3. Strategic Measures against Covid-19

5.3.1. Government Support and Initiative to Combat Covid-19

5.3.2. Proposal for generic drugs Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Generic Drugs Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.1.1. The low cost of generics, as an alternative to branded drugs

6.1.1.2. Large number of patent expired branded drugs

6.1.1.3. Initiatives by governments and other regulatory bodies

6.1.2. Market Restraints

6.1.2.1. Stringent governmental regulations and adverse effects associated with drugs

6.1.3. Market Opportunities

6.1.3.1. Use of RPA to ensure regulatory and standards compliance

Chapter 7. Global Generic Drugs Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.1.1. generic drugs Market Revenue by Market Players (2017 - 2021)

7.1.1.2. generic drugs Market Revenue Market Share by Market Players (2017 - 2021)

7.1.2. Key Organic/Inorganic Strategies Adopted by Players

7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation

7.1.2.2. Merger and Acquisition, Collaboration and Partnerships

7.1.3. Market Players Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of End-users

Chapter 8. Global Generic Drugs Market, By Drug Type

8.1. generic drugs Market, by Drug Type, 2017-2030

8.1.1. Simple Generics

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Super Generics

8.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Generic Drugs Market, By Brand

9.1. generic drugs Market, by Brand, 2017-2030

9.1.1. Pure generic drugs

9.1.1.1. Market Revenue and Forecast (2017-2030)

9.1.2. Branded generic drugs

9.1.2.1. Market Revenue and Forecast (2017-2030)

Chapter 10. Global Generic Drugs Market, By Route of Drug Administration

10.1. generic drugs Market, by Route of Drug Administration, 2017-2030

10.1.1. Oral

10.1.1.1. Market Revenue and Forecast (2017-2030)

10.1.2. Topical

10.1.2.1. Market Revenue and Forecast (2017-2030)

10.1.3. Parental

10.1.3.1. Market Revenue and Forecast (2017-2030)

10.1.4. Others

10.1.4.1. Market Revenue and Forecast (2017-2030)

Chapter 11. Global Generic Drugs Market, By Therapeutic Application

11.1. generic drugs Market, by Therapeutic Application, 2017-2030

11.1.1. Central nervous system (CNS)

11.1.1.1. Market Revenue and Forecast (2017-2030)

11.1.2. Cardiovascular

11.1.2.1. Market Revenue and Forecast (2017-2030)

11.1.3. Dermatology

11.1.3.1. Market Revenue and Forecast (2017-2030)

11.1.4. Oncology

11.1.4.1. Market Revenue and Forecast (2017-2030)

11.1.5. Respiratory

11.1.5.1. Market Revenue and Forecast (2017-2030)

11.1.6. Others

11.1.6.1. Market Revenue and Forecast (2017-2030)

Chapter 12. Global Generic Drugs Market, By Distribution Channel

12.1. generic drugs Market, by Distribution Channel, 2017-2030

12.1.1. Hospitals Pharmacies

12.1.1.1. Market Revenue and Forecast (2017-2030)

12.1.2. Retail Pharmacies

12.1.2.1. Market Revenue and Forecast (2017-2030)

12.1.3. Others

12.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 13. Global Generic Drugs Market, Regional Estimates and Trend Forecast

13.1. North America

13.1.1. Market Revenue Forecast by Drug Type(2017-2030)

13.1.2. Market Revenue Forecast by Brand (2017-2030)

13.1.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.1.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.1.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.1.6. U.S

13.1.6.1. Market Revenue Forecast (2017-2030)

13.1.7. Canada

13.1.7.1. Market Revenue Forecast (2017-2030)

13.2. Europe

13.2.1. Market Revenue Forecast by Drug Type (2017-2030)

13.2.2. Market Revenue Forecast by Brand (2017-2030)

13.2.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.2.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.2.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.2.6. UK

13.2.6.1. Market Revenue Forecast (2017-2030)

13.2.7. Germany

13.2.7.1. Market Revenue Forecast (2017-2030)

13.2.8. France

13.2.8.1. Market Revenue Forecast (2017-2030)

13.2.9. Rest of EU

13.2.9.1. Market Revenue Forecast (2017-2030)

13.3. Asia Pacific (APAC)

13.3.1. Market Revenue Forecast by Drug Type (2017-2030)

13.3.2. Market Revenue Forecast by Brand (2017-2030)

13.3.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.3.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.3.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.3.6. China

13.3.6.1. Market Revenue Forecast (2017-2030)

13.3.7. India

13.3.7.1. Market Revenue Forecast (2017-2030)

13.3.8. Japan

13.3.8.1. Market Revenue Forecast (2017-2030)

13.3.9. Rest of APAC

13.3.9.1. Market Revenue Forecast (2017-2030)

13.4. LATAM

13.4.1. Market Revenue Forecast by Drug Type (2017-2030)

13.4.2. Market Revenue Forecast by Brand (2017-2030)

13.4.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.4.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.4.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.4.6. Brazil

13.4.6.1. Market Revenue Forecast (2017-2030)

13.4.7. Rest of LATAM

13.4.7.1. Market Revenue Forecast (2017-2030)

13.5. Middle East and Africa (MEA)

13.5.1. Market Revenue Forecast by Drug Type (2017-2030)

13.5.2. Market Revenue Forecast by Brand (2017-2030)

13.5.3. Market Revenue Forecast by Route of Drug Administration (2017-2030)

13.5.4. Market Revenue Forecast by Therapeutic Application (2017-2030)

13.5.5. Market Revenue Forecast by Distribution Channel (2017-2030)

13.5.6. GCC

13.5.6.1. Market Revenue Forecast (2017-2030)

13.5.7. North Africa

13.5.7.1. Market Revenue Forecast (2017-2030)

13.5.8. South Africa

13.5.8.1. Market Revenue Forecast (2017-2030)

13.5.9. Rest of MEA

13.5.9.1. Market Revenue Forecast (2017-2030)

Chapter 14. Company Profiles

14.1. Abbott Laboratories

14.1.1. Company Overview, Business Information, Regional Presence

14.1.2. Product Portfolio Analysis

14.1.2.1. Product Details, Specification, Application

14.1.3. Revenue, Price, and Gross Margin (2017-2021)

14.1.4. Recent Developments and Strategies

14.2. Teva Pharmaceutical Industries Ltd.

14.2.1. Company Overview, Business Information, Regional Presence

14.2.2. Product Portfolio Analysis

14.2.2.1. Product Details, Specification, Application

14.2.3. Revenue, Price, and Gross Margin (2017-2021)

14.2.4. Recent Developments and Strategies

14.3. ALLERGAN

14.3.1. Company Overview, Business Information, Regional Presence

14.3.2. Product Portfolio Analysis

14.3.2.1. Product Details, Specification, Application

14.3.3. Revenue, Price, and Gross Margin (2017-2021)

14.3.4. Recent Developments and Strategies

14.4. Sandoz International GmbH

14.4.1. Company Overview, Business Information, Regional Presence

14.4.2. Product Portfolio Analysis

14.4.2.1. Product Details, Specification, Application

14.4.3. Revenue, Price, and Gross Margin (2017-2021)

14.4.4. Recent Developments and Strategies

14.5. Mylan N.V.

14.5.1. Company Overview, Business Information, Regional Presence

14.5.2. Product Portfolio Analysis

14.5.2.1. Product Details, Specification, Application

14.5.3. Revenue, Price, and Gross Margin (2017-2021)

14.5.4. Recent Developments and Strategies

14.6. STADA Arzneimittel AG

14.6.1. Company Overview, Business Information, Regional Presence

14.6.2. Product Portfolio Analysis

14.6.2.1. Product Details, Specification, Application

14.6.3. Revenue, Price, and Gross Margin (2017-2021)

14.6.4. Recent Developments and Strategies

14.7. Baxter International Inc.

14.7.1. Company Overview, Business Information, Regional Presence

14.7.2. Product Portfolio Analysis

14.7.2.1. Product Details, Specification, Application

14.7.3. Revenue, Price, and Gross Margin (2017-2021)

14.7.4. Recent Developments and Strategies

14.8. Eli Lilly and Company

14.8.1. Company Overview, Business Information, Regional Presence

14.8.2. Product Portfolio Analysis

14.8.2.1. Product Details, Specification, Application

14.8.3. Revenue, Price, and Gross Margin (2017-2021)

14.8.4. Recent Developments and Strategies

14.9. GlaxoSmithKline Plc.

14.9.1. Company Overview, Business Information, Regional Presence

14.9.2. Product Portfolio Analysis

14.9.2.1. Product Details, Specification, Application

14.9.3. Revenue, Price, and Gross Margin (2017-2021)

14.9.4. Recent Developments and Strategies

14.10. Pfizer Inc.

14.10.1. Company Overview, Business Information, Regional Presence

14.10.2. Product Portfolio Analysis

14.10.2.1. Product Details, Specification, Application

14.10.3. Revenue, Price, and Gross Margin (2017-2021)

14.10.4. Recent Developments and Strategies

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms